Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. (Q54588529)

1 June 2018

title

Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. (English)

1 reference

1 June 2018

1 reference

1 reference

9

1 reference

1 June 2018

Giorgio Valabrega

Giorgio Valabrega

8

0 references

Massimo Aglietta

Massimo Aglietta

10

0 references

Giuseppe Viale

11

Giuseppe Viale

1 reference

1 June 2018

Aron Goldhirsch

12

Aron Goldhirsch

1 reference

1 June 2018

Laura Adamoli

7

Laura Adamoli

1 reference

1 June 2018

Franco Nolè

13

Franco Nolè

1 reference

1 June 2018

author name string

Filippo Montemurro

1

1 reference

1 June 2018

Valentina Rossi

2

1 reference

1 June 2018

Maria Cossu Rocca

3

1 reference

1 June 2018

Rossella Martinello

4

1 reference

1 June 2018

Elena Verri

5

1 reference

1 June 2018

Stefania Redana

6

1 reference

1 June 2018

language of work or name

English

0 references

publication date

19 May 2011

1 reference

1 June 2018

published in

Cancer

1 reference

1 June 2018

volume

118

1 reference

1 June 2018

issue

1

1 reference

1 June 2018

page(s)

17-26

1 reference

1 June 2018

Endocrine-responsive breast cancer and strategies for combating resistance

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

inferred from DOI database lookup

7 January 2021

based on heuristic

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26162

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.26162

1 reference

1 June 2018

PubMed ID

21598238

1 reference

1 June 2018